{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:16:04Z","timestamp":1785402964889,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antisense oligonucleotide (AO)-mediated splice modulation has been established as a therapeutic approach for tackling genetic diseases. Recently, Exondys51, a drug that aims to correct splicing defects in the dystrophin gene was approved by the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). However, Exondys51 has relied on phosphorodiamidate morpholino oligomer (PMO) chemistry which poses challenges in the cost of production and compatibility with conventional oligonucleotide synthesis procedures. One approach to overcome this problem is to construct the AO with alternative nucleic acid chemistries using solid-phase oligonucleotide synthesis via standard phosphoramidite chemistry. 2\u2032-Fluoro (2\u2032-F) is a potent RNA analogue that possesses high RNA binding affinity and resistance to nuclease degradation with good safety profile, and an approved drug Macugen containing 2\u2032-F-modified pyrimidines was approved for the treatment of age-related macular degeneration (AMD). In the present study, we investigated the scope of 2\u2032-F nucleotides to construct mixmer and gapmer exon skipping AOs with either 2\u2032-<jats:italic>O<\/jats:italic>-methyl (2\u2032-<jats:italic>O<\/jats:italic>Me) or locked nucleic acid (LNA) nucleotides on a phosphorothioate (PS) backbone, and evaluated their efficacy in inducing exon-skipping in <jats:italic>mdx<\/jats:italic> mouse myotubes <jats:italic>in vitro<\/jats:italic>. Our results showed that all AOs containing 2\u2032-F nucleotides induced efficient exon-23 skipping, with LNA\/2\u2032-F chimeras achieving better efficiency than the AOs without LNA modification. In addition, LNA\/2\u2032-F chimeric AOs demonstrated higher exonuclease stability and lower cytotoxicity than the 2\u2032-<jats:italic>O<\/jats:italic>Me\/2\u2032-F chimeras. Overall, our findings certainly expand the scope of constructing 2\u2032-F modified AOs in splice modulation by incorporating 2\u2032-<jats:italic>O<\/jats:italic>Me and LNA modifications.<\/jats:p>","DOI":"10.1038\/s41598-019-42523-0","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T10:02:52Z","timestamp":1555322572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Systematic evaluation of 2\u2032-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro"],"prefix":"10.1038","volume":"9","author":[{"given":"Suxiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0953-9809","authenticated-orcid":false,"given":"Tamer R.","family":"Kosbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh N.","family":"Veedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"42523_CR1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2015.070","volume":"26","author":"KE Lundin","year":"2015","unstructured":"Lundin, K. E., Gissberg, O. & Smith, C. I. Oligonucleotide therapies: the past and the present. Hum Gene Ther 26, 475\u2013485 (2015).","journal-title":"Hum Gene Ther"},{"key":"42523_CR2","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1039\/C4MD00184B","volume":"5","author":"VK Sharma","year":"2014","unstructured":"Sharma, V. K., Sharma, R. K. & Singh, S. K. Antisense oligonucleotide: modifications and clinical trials. Med Chem Commum 5, 1454\u20131471 (2014).","journal-title":"Med Chem Commum"},{"key":"42523_CR3","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed, Y. Y. Eteplirsen: first global approval. Drugs 76, 1699\u20131704 (2016).","journal-title":"Drugs"},{"key":"42523_CR4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nn.4508","volume":"20","author":"DR Corey","year":"2017","unstructured":"Corey, D. R. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosi 20, 497\u2013499 (2017).","journal-title":"Nat Neurosi"},{"key":"42523_CR5","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias, N. & Stein, C. A. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1, 347\u2013355 (2002).","journal-title":"Mol Cancer Ther"},{"key":"42523_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/oli.1.2000.10.117","volume":"10","author":"F Eckstein","year":"2000","unstructured":"Eckstein, F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Nucleic Acid Drug Dev 10, 117\u2013121 (2000).","journal-title":"Nucleic Acid Drug Dev"},{"key":"42523_CR7","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/nar\/26.9.2224","volume":"26","author":"M Majlessi","year":"1998","unstructured":"Majlessi, M., Nelson, N. C. & Becker, M. M. Advantages of 2\u2032-O-methyl oligoribonucleotide probes for detecting RNA targets. Nucleic Acids Res 26, 2224\u20132229 (1998).","journal-title":"Nucleic Acids Res"},{"key":"42523_CR8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/jm00059a007","volume":"36","author":"AM Kawasaki","year":"1993","unstructured":"Kawasaki, A. M. et al. Uniformly modified 2\u2032-deoxy-2\u2032-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem 36, 831\u2013841 (1993).","journal-title":"J Med Chem"},{"key":"42523_CR9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nchembio.939","volume":"8","author":"F Rigo","year":"2012","unstructured":"Rigo, F. et al. Synthetic oligonucleotides recruit ILF2\/3 to RNA transcripts to modulate splicing. Nat Chem Biol 8, 555\u2013561 (2012).","journal-title":"Nat Chem Biol"},{"key":"42523_CR10","doi-asserted-by":"crossref","unstructured":"Jirka, S. M. G. et al. Evaluation of exon skipping activity of 2\u2032-deoxy-2\u2032-fluoro antisense oligonucleotides for Duchenne muscular dystrophy. Abstracts \/ Neuromuscul Disord 24, 791\u2013924. G.P.109 (2014).","DOI":"10.1038\/mtna.2015.39"},{"key":"42523_CR11","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1038\/mtna.2015.39","volume":"4","author":"SMG Jirka","year":"2015","unstructured":"Jirka, S. M. G. et al. Evaluation of 2\u2032-deoxy-2\u2032-fluoro antisense oligonucleotides for exon skipping in Duchenne muscular dystrophy. Mol Ther Nucleic Acids 4, e265 (2015).","journal-title":"Mol Ther Nucleic Acids"},{"key":"42523_CR12","first-page":"890","volume":"296","author":"RS Geary","year":"2001","unstructured":"Geary, R. S. et al. Pharmacokinetic properties of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296, 890\u2013897 (2001).","journal-title":"J Pharmacol Exp Ther"},{"key":"42523_CR13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton, J. & Weller, D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7, 187\u2013195 (1997).","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"42523_CR14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cbdv.200900343","volume":"7","author":"RN Veedu","year":"2010","unstructured":"Veedu, R. N. & Wengel, J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers 7, 536\u2013542 (2010).","journal-title":"Chem Biodivers"},{"key":"42523_CR15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4161\/rna.6.3.8807","volume":"6","author":"RN Veedu","year":"2009","unstructured":"Veedu, R. N. & Wengel, J. Locked nucleic acid as a novel class of therapeutic agents. RNA Biol 6, 321\u2013323 (2009).","journal-title":"RNA Biol"},{"key":"42523_CR16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.omtn.2017.09.002","volume":"9","author":"BT Le","year":"2017","unstructured":"Le, B. T. et al. Rational design of short locked nucleic acid-modified 2\u2032-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro. Mol Ther Nucleic Acids 9, 155\u2013161 (2017).","journal-title":"Mol Ther Nucleic Acids"},{"key":"42523_CR17","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1016\/j.bmc.2009.06.045","volume":"17","author":"N Langkjaer","year":"2009","unstructured":"Langkjaer, N., Pasternak, A. & Wengel, J. UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem 17, 5420\u20135425 (2009).","journal-title":"Bioorg Med Chem"},{"key":"42523_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0968-0896(95)00171-9","volume":"4","author":"B Hyrup","year":"1996","unstructured":"Hyrup, B. & Nielsen, P. E. Peptide nucleic acids (PNA): synthesis, properties and potential applications. Bioorg Med Chem 4, 5\u201323 (1996).","journal-title":"Bioorg Med Chem"},{"key":"42523_CR19","doi-asserted-by":"crossref","first-page":"34049","DOI":"10.1039\/C7RA06091B","volume":"7","author":"BT Le","year":"2017","unstructured":"Le, B. T. et al. Antisense oligonucleotide modified with serinol nucleic acid (SNA) induces exon skipping in mdx myotubes. RSC Adv 7, 34049\u201334052 (2017).","journal-title":"RSC Adv"},{"key":"42523_CR20","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1021\/ja025569+","volume":"124","author":"D Renneberg","year":"2002","unstructured":"Renneberg, D. & Leumann, C. J. Watson\u2212crick base-pairing properties of tricyclo-DNA. J Am Chem Soc 124, 5993\u20136002 (2002).","journal-title":"J Am Chem Soc"},{"key":"42523_CR21","doi-asserted-by":"crossref","first-page":"95169","DOI":"10.1039\/C6RA22346J","volume":"6","author":"BT Le","year":"2016","unstructured":"Le, B. T., Filichev, V. V. & Veedu, R. N. Investigation of twisted intercalating nucleic acid (TINA)-modified antisense oligonucleotides for splice modulation by induced exon-skipping in vitro. RSC Adv 6, 95169\u201395172 (2016).","journal-title":"RSC Adv"},{"key":"42523_CR22","doi-asserted-by":"crossref","first-page":"13467","DOI":"10.1039\/C6CC07447B","volume":"52","author":"BT Le","year":"2016","unstructured":"Le, B. T. et al. Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and D-altritol nucleic acid-modified 2\u2032-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro. Chem Commun 52, 13467\u201313470 (2016).","journal-title":"Chem Commun"},{"key":"42523_CR23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3390\/molecules21111582","volume":"21","author":"S Chen","year":"2016","unstructured":"Chen, S. et al. Synthesis of a morpholino nucleic acid (MNA)-uridine phosphoramidite, and exon skipping using MNA\/2\u2032-O-methyl mixmer antisense oligonucleotide. Molecules. 21, 1582 (2016).","journal-title":"Molecules."},{"key":"42523_CR24","doi-asserted-by":"crossref","unstructured":"Masaki, Y. et al. Enhancement of exon skipping in mdx52 mice by 2\u2032-O-methyl-2-thioribothymidine incorporation into phosphorothioate oligonucleotides. Med Chem Commun 6, 630-633 (2015).","DOI":"10.1039\/C4MD00468J"},{"key":"42523_CR25","doi-asserted-by":"crossref","first-page":"54542","DOI":"10.1039\/C7RA10964D","volume":"7","author":"BT Le","year":"2017","unstructured":"Le, B. T. et al. Nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2\u2032-deoxyuridine nucleotides induce exon-skipping in vitro. RSC Adv 7, 54542\u201354545 (2017).","journal-title":"RSC Adv"},{"key":"42523_CR26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","volume":"381","author":"E Mercuri","year":"2013","unstructured":"Mercuri, E. & Muntoni, F. Muscular dystrophies. Lancet 381, 845\u2013860 (2013).","journal-title":"Lancet"},{"key":"42523_CR27","first-page":"139","volume":"4","author":"BT Le","year":"2016","unstructured":"Le, B. T. et al. Antisense oligonucleotide development for the treatment of muscular dystrophies. Expert Opin Orphan. Drugs 4, 139\u2013152 (2016).","journal-title":"Drugs"},{"key":"42523_CR28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.molmed.2015.04.006","volume":"21","author":"SD Wilton","year":"2015","unstructured":"Wilton, S. D., Veedu, R. N. & Fletcher, S. The emperor\u2032s new dystrophin: finding sense in the noise. Trends Mol Med 21, 417\u2013426 (2015).","journal-title":"Trends Mol Med"},{"key":"42523_CR29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nrm2024","volume":"7","author":"KE Davies","year":"2006","unstructured":"Davies, K. E. & Nowak, K. J. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 7, 762\u2013773 (2006).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"42523_CR30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/156652312800840621","volume":"12","author":"V Arechavala-Gomeza","year":"2012","unstructured":"Arechavala-Gomeza, V. et al. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges. Curr Gene Ther 12, 152\u2013160 (2012).","journal-title":"Curr Gene Ther"},{"key":"42523_CR31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/1874467210902010110","volume":"2","author":"C Mitrpant","year":"2009","unstructured":"Mitrpant, C., Fletcher, S. & Wilton, S. D. Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping. Curr Mol Pharmacol 2, 110\u2013121 (2009).","journal-title":"Curr Mol Pharmacol"},{"key":"42523_CR32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrg3460","volume":"14","author":"RJ Fairclough","year":"2013","unstructured":"Fairclough, R. J., Wood, M. J. & Davies, K. E. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet 14, 373\u2013378 (2013).","journal-title":"Nat Rev Genet"},{"key":"42523_CR33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74, 637\u2013647 (2013).","journal-title":"Ann Neurol"},{"key":"42523_CR34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","volume":"87","author":"R Kole","year":"2015","unstructured":"Kole, R. & Krieg, A. M. Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev 87, 104\u2013107 (2015).","journal-title":"Adv Drug Deliv Rev"},{"key":"42523_CR35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14712598.2017.1250880","volume":"17","author":"S Fletcher","year":"2017","unstructured":"Fletcher, S. et al. Translational development of splice-modifying antisense oligomers. Expert Opin Biol Ther 17, 15\u201330 (2017).","journal-title":"Expert Opin Biol Ther"},{"key":"42523_CR36","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1038\/mtna.2012.40","volume":"1","author":"S Fletcher","year":"2012","unstructured":"Fletcher, S. et al. Targeted exon skipping to address \u201cleaky\u201d mutations in the dystrophin gene. Mol Ther Nucleic Acids 1, e48 (2012).","journal-title":"Mol Ther Nucleic Acids"},{"key":"42523_CR37","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1007\/s00018-013-1396-z","volume":"70","author":"A Govoni","year":"2013","unstructured":"Govoni, A. et al. Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Cell Mol Life Sci 70, 4585\u20134602 (2013).","journal-title":"Cell Mol Life Sci"},{"key":"42523_CR38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2016.04.001","volume":"118","author":"MC Miceli","year":"2016","unstructured":"Miceli, M. C. & Nelson, S. F. The case for eteplirsen: paving the way for precision medicine. Mol Genet Metab 118, 70\u201371 (2016).","journal-title":"Mol Genet Metab"},{"key":"42523_CR39","unstructured":"GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne Muscular Dystrophy. Available online, https:\/\/globenewswire.com\/news-release\/2013\/09\/20\/574726\/10049265\/en\/GSK-and-Prosensa-Announce-Primary-Endpoint-Not-Met-in-Phase-III-Study-of-Drisapersen-in-Patients-With-Duchenne-MuscularDystrophy.html (accessed on 20 July 2018)."},{"key":"42523_CR40","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo, T. et al. Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42, 8174\u20138187 (2014).","journal-title":"Nucleic Acids Res"},{"key":"42523_CR41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1073\/pnas.98.1.42","volume":"98","author":"CJ Mann","year":"2001","unstructured":"Mann, C. J. et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98, 42\u201347 (2001).","journal-title":"Proc Natl Acad Sci USA"},{"key":"42523_CR42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","volume":"75","author":"PC Zamecnik","year":"1978","unstructured":"Zamecnik, P. C. & Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75, 280\u2013284 (1978).","journal-title":"Proc Natl Acad Sci USA"},{"key":"42523_CR43","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","volume":"90","author":"Z Dominski","year":"1993","unstructured":"Dominski, Z. & Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 90, 8673\u20138677 (1993).","journal-title":"Proc Natl Acad Sci USA"},{"key":"42523_CR44","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.gt.3302313","volume":"11","author":"A Aartsma-Rus","year":"2004","unstructured":"Aartsma-Rus, A. et al. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene ther 11, 1391\u20131398 (2004).","journal-title":"Gene ther"},{"key":"42523_CR45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","volume":"81","author":"G Bulfield","year":"1984","unstructured":"Bulfield, G. et al. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad Sci USA 81, 1189\u20131192 (1984).","journal-title":"Proc. Natl Acad Sci USA"},{"key":"42523_CR46","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1083\/jcb.125.6.1275","volume":"125","author":"TA Rando","year":"1994","unstructured":"Rando, T. A. & Blau, H. M. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 125, 1275\u20131287 (1994).","journal-title":"J Cell Biol"},{"key":"42523_CR47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671\u2013675 (2012).","journal-title":"Nat Methods"}],"updated-by":[{"DOI":"10.1038\/s41598-020-63706-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42523-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:40:07Z","timestamp":1671266407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42523-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42523"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42523-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-020-63706-0","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"assertion":[{"value":"7 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6078"}}